TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06429176: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

Sponsor: SpliSense Ltd. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 64 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT06429176 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06429176 Rescue Dossier →